Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 Phase 1 in Bone Metastases
NCT03550508Phase 1Unknown
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2018
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of narlumosbart in bone metastasis, sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events at 28 days. Status: unknown.
02
Drugs
narlumosbart
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT03550508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550508.